ROS1 mutations promote an immunosuppressive tumor microenvironment via MYC to confer immune evasion in head and neck cancer

Cancer Drug Resistance · Published 2025-08-22 · DOI 10.20517/cdr.2025.124

Authors being retrieved — see the publisher record. https://doi.org/10.20517/cdr.2025.124

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

KLF5 promotes tumor proliferation and oxaliplatin resistance via chromatin remodeling in KRAS-mutated colorectal cancer · Cancer Drug Resistance · 2025 · Same journal
Immunotherapy resistance and strategies in malignant pleural mesothelioma · Cancer Drug Resistance · 2026 · Same journal
Effects of FAP+ cancer-associated fibroblasts on anti-PD-1 immunotherapy and CD4+ T cell polarization in gastric cancer · Cancer Drug Resistance · 2025 · Same journal
TRAP1 ablation improves mitochondrial cristae and oxidative phosphorylation in pancreatic cancer stem cells · Cancer Drug Resistance · 2026 · Same journal
Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated fibroblasts to resist drug resistance · Cancer Drug Resistance · 2026 · Same journal
Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy · Cancer Drug Resistance · 2026 · Same journal
Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update · Cancer Drug Resistance · 2025 · Same journal
Corosolic acid increases the therapeutic effect of cisplatin on gastric cancer by regulating Gpx4-dependent ferroptosis · Cancer Drug Resistance · 2025 · Same journal
Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies · Cancer Drug Resistance · 2026 · Same journal
Deep spatial proteomics reveals a suppressive immune niche linked to immune evasion in renal cell carcinoma · Cancer Drug Resistance · 2026 · Same journal